Jul 5, 2023 · In medium containing 2 mM glutamine, addition of MC38 cells induced upregulation of CD86, which was impaired in the presence of a physiological concentration (0.6 mM) of glutamine.

Jul 22, 2021 · To block CTLA-4 function and examine the short-term effects on CD80 and CD86 expression in MC38 tumors, we used the CTLA-4 antibody UC10-4F10-11 (henceforth 4F10) (Walunas et al., 1994).

To determine whether the antitumor efficacy of anti–PD-1 can be enhanced when CD28 binds its natural ligand (s), we used the well-established C57BL6 syngeneic MC38 mouse tumor model; MC38 cells were engineered to overexpress murine CD86, one of the costimulatory ligands for CD28 (MC38/CD86, fig. S1A).

Jul 17, 2024 · Tumor-draining lymph nodes (TDLNs) of MC38 tumor-bearing C57BL/6 mice treated with PBS, OX+GA, OX-NCP, GA-NCP, or OX/GA were collected and analyzed for MHCII + CD86 + expressions in DCs (CD45 + CD11b + CD11c +) 4 days after treatment.

Of interest is the expression of CD86 by moDCs, which could provide co-stimulation to T cells via the CD28 costimulatory receptor known to mediate PD1 blockade efficacy. 13 14 PD1-responsive MC38 tumors are enriched in checkpoint-expressing TILs and show increased abundancy correlation with myeloid cells compared with B16 tumors

Mechanistic studies using mixed bone marrow chimeras identified that CD40 and CD80/86, but not CD70 signaling in Batf3-dependent conventional type 1 dendritic cells (cDC1s) is required for the antitumor efficacy of neoantigen vaccine and generation of …

Jun 30, 2017 · BMDCs stimulated with MC38/shTGFβ1 cells showed significantly increased expression of costimulatory molecules (CD40, CD80, CD86) as well as MHC class II compared to control cells incubated with MC38/shN or untransduced MC38 cells (Figure 1 E).

As we expected, mature BMDCs expressed higher CD40, CD80 and CD86 than immature BMDCs. Thus, the PBMCs released more IFN- γ and TNF- α when stimulated with DC-SNU in vitro again. What's more, the PBMCs induced stronger and specific cytotoxicity towards MC38 NY-ESO-1 tumor cells.

Feb 13, 2024 · CD86, but not CD80, blockade prevented the effector Treg response, enriched the tumor-draining lymph node migratory conventional DCs that were positive for PD-L1 and CD80 (PD-L1 + CD80 +), and promoted CTL priming.

Feb 13, 2023 · The metastatic Mc38 cells made full use of liver vessels and perivascular TAMs; they further adopted VM vessels to match the rapid growth of tumor vasculature.